Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proglumetacin is a nonsteroidal anti-inflammatory drug (NSAID) of the indole acetic acid derivative class. It is primarily used to manage pain and inflammation associated with musculoskeletal and joint disorders such as rheumatoid arthritis and osteoarthritis. Proglumetacin acts as a prodrug that is metabolized in the body to indometacin (an active NSAID) and proglumide (which has antisecretory effects that help protect the gastric mucosa). Its mechanism of action involves inhibition of cyclooxygenase enzymes at sites of inflammation—thereby reducing prostaglandin synthesis—and it may also inhibit 5-lipoxygenase activity. The drug was first developed by Fresenius[1][2][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on proglumetacin.